META: The Options Market Is Not Shrugging

The Signal

On August 10, at 10:53 a.m. Eastern, a trader executed a block order for 1,001 weekly META put contracts at the $602.50 strike, with the stock trading near $603.70. The position cost approximately $701,000 at a $7.00 offer. By the close, META had fallen to $594.92. The puts were worth $11.13. That is a 59% gain, roughly $414,000 of mark-to-market profit, in a single session.

One block trade does not define a thesis. But this one did not arrive in a vacuum. It landed the same day the Ninth Circuit denied Meta’s emergency stay request and dismissed its interlocutory Section 230 appeals, clearing the path for the Oakland federal trial to begin August 18. Whoever placed that trade was not reacting to the news. They were already there.

That is the question worth asking this week: when the stock market keeps buying every META dip, why are certain options participants positioning for something the equity market has not priced?

Why It Matters

META’s implied volatility skew is showing a modest but meaningful tilt toward puts. The 25-delta put IV currently reads 39.4% versus the 25-delta call IV at 38.2%, a difference of 1.2 percentage points, putting the put/call IV ratio at 1.03. On its own, that reads as nearly balanced. In context, it is notable for a stock that spent the last three years with a persistently flat or call-skewed options surface, driven by institutional demand for upside exposure in what was a sustained bull trend.

That skew has shifted. It shifted as the stock moved from a 52-week high of $796.25 to a 52-week low of $520.26 in early August, then rebounded to the current $589.85 range. The round trip happened in roughly two weeks. Most of the volatility originated from three compounding events: a Q2 earnings miss, a legal charge embedded in that miss, and a legal calendar that now stretches into at least February 2027 with no resolution in sight.

The overall put/call volume ratio sits around 0.58, meaning calls still dominate by raw volume. But that headline figure obscures the more relevant signal: where open interest is building, and at what strikes. Call concentration around the $600 strike, the most active contract in recent sessions with over 33,000 contracts traded in a single day at expiration, can reflect dealer hedging or covered call writing by existing stockholders as much as directional bullish bets. When call volume is that concentrated at a round number just above current price, the interpretation requires more nuance than the raw ratio suggests.

The Company Behind the Signal

META reported Q2 2026 results on July 29. Revenue came in at $60.8 billion, up 28% year over year and slightly ahead of the $60.2 billion consensus. That is the part of the report that looks fine. Everything below the revenue line is where the complexity begins.

Diluted EPS of $6.18 missed consensus of roughly $7.14 to $7.22 by approximately 13 to 14%, snapping a six-consecutive-quarter streak of EPS beats. Total costs and expenses surged 55% to $42.03 billion, nearly twice the rate of revenue growth. Embedded in that cost figure: a $2.4 billion legal contingency charge and a $1.18 billion severance charge tied to an 8,000-person headcount reduction. Free cash flow, which was $8.5 billion in Q2 2025, collapsed to $784 million. Capital expenditures hit $31.1 billion in the quarter alone.

Management raised full-year capex guidance to $130 to $145 billion, narrowed from the prior $125 to $145 billion range at the low end, meaning the floor moved up $5 billion in a single quarter. Full-year expense guidance rose to $165 to $169 billion, with management explicitly citing the $2.4 billion legal charge as driving the upward revision. Q3 revenue guidance came in at $61 to $64 billion, a midpoint of $62.5 billion, below the Street’s $63.1 billion expectation. The stock fell nearly 8% on July 30 and then continued lower, hitting a 52-week low near $520 in the first week of August before recovering to its current range around $590.

The core advertising engine is not broken. Ad revenue reached $59.36 billion, up 27%, as ad impressions grew 14% and average price per ad rose 12%. Daily active users across the Family of Apps reached 3.60 billion, up 3%. These are legitimate growth metrics. But the cost structure running underneath them, driven by AI infrastructure spending and an expanding legal liability, is compressing the margin that made META a consensus institutional favorite through 2024 and most of 2025.

The legal charge itself carries a specific implication. Management raised expense guidance explicitly to incorporate $2.4 billion in legal contingencies from Q2. That figure is not the ceiling. The Oakland trial opens August 18. The February 2027 school district bellwether sits behind it. Meta’s insurers have declined to cover child safety claims, arguing the damages arise from intentional design choices. Every additional adverse verdict flows directly to the income statement and the balance sheet, uninsured.

Market Expectations

The options market is currently implying a stock trading at the intersection of two distinct risk regimes that do not normally coexist: a beaten-down large-cap with genuine fundamental pressure, and a pending legal event that the equity market keeps treating as a non-event. Understanding how those two regimes interact is the core analytical challenge heading into the week of August 18.

Historical volatility has been elevated. The stock moved roughly 15% peak-to-trough in two weeks after earnings, an event-driven range far exceeding what a typical earnings cycle produces for a stock of this size. For context, a stock trading near $590 with an annualized implied volatility around 36 to 39% is pricing roughly 2.3% to 2.5% of daily movement at one standard deviation. Over the past two weeks, META has regularly exceeded that daily range in both directions.

The more interesting structural question is what the options market is implying about the trial itself. Markets rarely price legal events cleanly, because legal timelines are unpredictable and outcomes are binary in ways that options models struggle to capture. A seven-week trial that could produce injunctive relief, monetary penalties, both, or neither, spread across months of proceedings and probable appeals, does not translate neatly into a standard expected move calculation. What it does create is a persistent bid for tail protection that is visible in the slight put skew and in the block activity that has surfaced in the days surrounding key legal developments.

The next identifiable hard catalyst is November 4, 2026, which is META’s next earnings date. Between now and then, the Oakland trial proceedings, any ruling on injunctive relief, Zuckerberg’s testimony, and the parallel user bellwether trial that began July 27 in the same courthouse, all create a sustained news flow that can move the stock on individual sessions. That sustained uncertainty without a clean resolution date is exactly the environment where implied volatility tends to remain elevated longer than the equity market’s complacency would suggest it should.

Strategic Considerations

This situation calls for precision in strategy selection, because the range of outcomes is genuinely wide and the timeline is extended. Three frameworks are relevant depending on how a trader characterizes the primary risk.

For those expecting continued volatility without a strong directional view: The environment described above, elevated historical volatility, sustained uncertainty, a stock that has whipsawed 15% in two weeks, favors structures that benefit from continued movement in either direction without requiring a precise directional call. A long straddle or strangle positioned around the current price captures that thesis if the stock continues to move materially. The risk in this approach is time decay: implied volatility that appears elevated by recent standards may compress if the trial produces a period of procedural calm, eroding the value of both legs simultaneously. The seven-week trial duration is long enough that near-dated straddles face serious decay pressure. If you believe further large moves are coming but are uncertain of timing, longer-dated structures reduce that decay drag at the cost of higher premium outlay.

For those primarily concerned about downside risk: The bear case is specific. It is not that META’s advertising business fails. It is that a federal judge issues injunctive relief ordering platform-level changes that structurally impair engagement, data collection, or algorithmic amplification, the exact features that generate the ad pricing power growing 12% per quarter. A defined-risk put debit spread, buying a put at or near current price and selling a lower-strike put to reduce premium outlay, captures that thesis with capped loss equal to the net premium paid. The trade does not require a financial catastrophe. It requires only that the injunction risk the market is currently dismissing becomes something the equity market has to start pricing. The spread’s defined risk structure means the position does not require a margin call or a stop-loss discipline to stay within the intended risk parameters.

For those maintaining a bullish view on the core business: META’s ad engine is genuinely strong. Revenue grew 28% in Q2. Ad impressions and pricing power both held. The Q2 EPS miss, stripped of the $2.4 billion legal charge and $1.18 billion severance, would likely have beaten consensus. If you believe the legal risk resolves without injunctive relief, and that H2 2026 capex spending stabilizes free cash flow, the stock trading at roughly 26% of its 52-week range with a market cap of approximately $1.5 trillion represents a different kind of opportunity. A cash-secured put at a strike below current price defines the entry level and generates premium income while waiting for the stock to stabilize. If assigned, the effective cost basis reflects both the discount to current price and the premium received. If not assigned, the premium is retained. The risk is that the stock continues lower and the position is assigned at a level that still sits above where the stock eventually finds support.

One structure worth examining for those who hold existing META equity and want to manage risk through the trial period without selling shares outright: a collar. Buying a put below current price for downside protection while selling a call above current price to finance part of that put cost creates a defined range around the existing position. Given that the put skew is currently modest, the relative cost of downside protection is not dramatically elevated, which means the financing leg of a collar can be structured without sacrificing excessive upside. The tradeoff is capped participation if the stock rallies sharply on a favorable trial outcome or on a Q3 earnings recovery. For long-term holders who are willing to accept that tradeoff in exchange for defined exposure through an uncertain seven-week legal proceeding, the collar fits the risk profile.

Key Risks Across All Approaches

The legal timeline is the primary source of risk that options models handle poorly. A seven-week trial does not deliver a verdict in week one. Proceedings advance incrementally, testimony unfolds over days, and the actual ruling may come months after the trial concludes. Implied volatility could compress in periods of procedural quiet even as the underlying risk accumulates. Positions structured around the expectation of near-term movement may decay while the real event, a judge’s ruling on injunctive relief, remains months away.

The Ninth Circuit’s August 10 ruling that Section 230 provides a defense to liability but not immunity from suit means roughly 3,000 additional lawsuits remain on track. A settlement during trial, while not the base case, would create a sharp volatility compression event that hurts any long-premium structure regardless of direction. Conversely, any concession by Zuckerberg or Mosseri on internal research showing awareness of platform harms, exactly the category of testimony that turned juries in New Mexico and Los Angeles, could be the catalyst that finally moves the equity market’s complacency.

Capex risk is independent of the legal situation and compounds it. Free cash flow of $784 million in a quarter where the company spent $31.1 billion on capital expenditures is a balance sheet dynamic that has nothing to do with the Oakland trial. The November 4 earnings report will be the first clean read on whether legal charges and severance costs were genuinely one-time events or whether the cost structure has fundamentally reset. Until then, the earnings overhang is real and independent.

What to Watch

Four developments over the next six weeks will determine whether the current options positioning proves prescient or premature.

• Zuckerberg’s testimony content. Specifically, any acknowledgment of internal research linking platform design to harm in younger users. That category of evidence turned two previous juries. Watch for it in August during the opening phase of the Oakland trial.
• Whether the court issues any interim orders. Judge Gonzalez Rogers has significant latitude in an advisory jury structure. Any interim ruling, even procedural, that signals her view of the states’ remedies request would be a material event for implied volatility.
• The parallel July 27 user bellwether trial verdict. Two Oakland juries evaluating overlapping facts simultaneously is an unusual dynamic. A verdict in the user case, even a partial one, gives the market a read on how the design-defect theory is resonating with ordinary jurors in this specific jurisdiction.
• Q3 capex tracking and any guidance revision language. The November 4 earnings report is the next major equity catalyst. Between now and then, any public signal from management about whether capex is running toward the high or low end of the $130 to $145 billion range will move the stock and reset implied volatility levels heading into earnings.

Bottom Line

The equity market has interpreted META’s recovery from $520 to $590 as evidence that the worst is behind it. The options market is telling a more careful story. The August 10 put block that paid 59% in a single session, the slight tilt toward put skew in the 25-delta surface, and the sustained call concentration at the $600 round number that may reflect dealer hedging more than outright bullish conviction, these are not the signals of a market that is uniformly comfortable with the current price and the risk calendar in front of it.

The Oakland trial opens Monday. The options market is not shrugging. The question for traders is whether to position with it, against it, or simply to ensure that existing equity exposure has a defined boundary for the seven weeks it will take to find out what a federal judge decides to order Meta to change about the products that generate 98% of its revenue.

Tactical Checklist

• Current price: ~$589.85 | 52-week range: $520.26 to $796.25 | Market cap: ~$1.5 trillion
• 25-delta put IV: 39.4% vs. call IV: 38.2% (put skew: +1.2pp)
• Put/call volume ratio: ~0.58 (call-dominant but skew tilting toward puts)
• Key legal event: Oakland trial opens August 18, expected to run seven weeks
• Next earnings: November 4, 2026 (Q3 revenue guidance: $61-$64B; Street midpoint: $63.1B)
• Bearish defined-risk view: Put debit spread captures injunction risk with capped premium outlay
• Neutral volatility view: Long strangle or straddle benefits from continued large moves; use longer-dated expiration to reduce decay drag over the seven-week trial window
• Bullish defined-entry view: Cash-secured put below current price generates premium while establishing a lower cost basis on potential assignment
• Equity holder protection: Collar structure (put + short call) provides defined exposure range through the trial without requiring a sale of underlying shares
• Risk factors to monitor: Trial settlement, Zuckerberg/Mosseri testimony on internal research, any interim judicial orders, and Q3 capex tracking language